Get the Daily Brief
Latest Biotech News
Bead‑based CRISPR Diagnostic Increases Sensitivity and Multiplexing
Researchers introduced a bead‑based enhancement to CRISPR diagnostics that significantly raises sensitivity and supports multiplexed detection, addressing key limitations of many CRISPR‑based...
Takeda Signs Second Deal for AI‑Designed Proteins — Protein Engineering Heats Up
Takeda expanded its multi‑year collaboration with AI protein design specialist Nabla Bio by signing a second research agreement to discover AI‑designed proteins. The deal extends a partnership...
U.S. Regulatory Squeeze: FDA Approvals Dip as Shutdown Strains Agency Capacity
Industry data show the FDA is on pace to approve its fewest new drugs and biologics since 2022, driven by lower application throughput and a tighter review calendar. Multiple companies await...
Trogenix Raises $95M to Advance Trojan‑Horse Platform for Aggressive Tumors
Edinburgh‑based Trogenix closed a $95 million Series A to advance its Odysseus platform, which deploys synthetic super enhancers via AAV vectors to activate therapeutic payloads selectively in...
Novo Nordisk raises MASH bet — Up to $5.2bn Akero deal
Novo Nordisk agreed to acquire Akero Therapeutics for up to $5.2 billion to secure efruxifermin (EFX), an FGF21 analogue now in Phase III for metabolic dysfunction‑associated steatohepatitis...
Bristol Myers buys Orbital — $1.5bn play for in vivo cell therapy
Bristol Myers Squibb acquired Orbital Therapeutics in a reported $1.5 billion transaction to gain an in vivo cell‑therapy platform aimed at autoimmune disease. The deal brings BMS a program that...
FDA under strain — Approval pace slows as shutdown bites regulator
The FDA is on pace for its lowest tally of new drug and biologic approvals since 2022 while a US federal funding impasse has constrained the agency’s operations. Companies and applicants face...
Regeneron to seek FDA OK after gene therapy restores hearing in children
Regeneron published trial results showing a gene therapy substantially improved hearing in children born with a specific genetic form of deafness and plans to file for regulatory approval....
Cambridge hematoids: lab‑grown embryo models generate human blood stem cells
Scientists at the University of Cambridge created three‑dimensional embryo‑like structures that recapitulate early human development and produce blood stem cells, according to new Cell Reports...
mRNA and molecular discoveries revive male fertility prospects
Researchers at the University of Osaka and Baylor College of Medicine reported an mRNA therapy that restored sperm production and fertility in mouse models carrying genetic defects. The...
Excellergy debuts with $70m to challenge Xolair — New allergy drug class
Excellergy launched with a $70 million Series A led by Samsara Biocapital to advance effector cell response inhibitors (ECRIs), a new therapeutic class designed to rapidly disarm IgE‑driven...
South Korea picks PacBio for national pangenome; Bio‑Techne expands nanopore tie‑up
The Korea Disease Control and Prevention Agency selected Pacific Biosciences' HiFi long‑read sequencing to build a telomere‑to‑telomere Korean pangenome reference, planning more than 1,000 whole...
Antibiotic pipeline and resistance tighten: Blacksmith gains QIDP as WHO warns
Blacksmith Medicines received FDA Qualified Infectious Disease Product (QIDP) and Fast Track designations for FG‑2101, an LpxC inhibitor targeting Gram‑negative pathogens, securing potential...
Compute accelerates biology — GPUs and language models speed genomics
Unum and Nebius announced a GPU‑optimized release of StringZilla, accelerating sequence alignment and fingerprinting tasks critical to large‑scale omics and drug discovery workflows. The port...
Bristol Myers Squibb buys Orbital Therapeutics – $1.5bn bet on in vivo CAR T
Bristol Myers Squibb agreed to acquire Orbital Therapeutics for $1.5 billion in a deal that brings an in vivo cell-therapy platform into BMS’s immunology pipeline. Orbital’s technology delivers...
South Korea selects PacBio HiFi sequencing: national pangenome to map 1,000+ genomes
South Korea's Korea Disease Control and Prevention Agency and Korea National Institute of Health selected Pacific Biosciences’ HiFi long‑read sequencing as the primary platform for a national...
Bio‑Techne extends nanopore pact: portfolio push to commercialize heritable disorder tests
Bio‑Techne expanded its collaboration with Oxford Nanopore Technologies to develop and commercialize a broader portfolio of targeted enrichment kits for screening and diagnosing heritable genetic...
AI predicts pediatric sepsis: models flag high‑risk infants for earlier intervention
New machine‑learning models were shown to forecast pediatric sepsis risk, enabling clinicians to identify at‑risk infants earlier and prompt proactive care. The research demonstrates that AI...
Moderna previews mRNA antigen therapy: melanoma data disclosed ahead of ESMO
Moderna shared early clinical data for its mRNA cancer antigen therapy, mRNA‑4359, combined with Merck’s PD‑1 inhibitor prior to ESMO presentation. The company reported responses in patients with...
Regeneron to seek FDA approval: gene therapy restores hearing in children
Regeneron announced clinical results in The New England Journal of Medicine showing its gene therapy improved hearing in a cohort of children born with a rare genetic form of deafness. Nine of 12...